Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Home
/
update
/
details

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

NextEdge Admin

31 Dec 2024

2 min 23 sec

Hengrui Pharma,DLL3-Targeting ADC,Precision Oncology

IDEAYA Biosciences, a precision medicine oncology company, has entered an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, SHA: 600276) for SHR-4849, a DLL3-targeting Topo-I-payload ADC. IDEAYA will develop and commercialize SHR-4849 globally, excluding Greater China.

SHR-4849 is a promising therapeutic candidate targeting DLL3, which is highly expressed in SCLC (~85%) and NETs (20-40%) with limited expression in normal tissues. The ADC is being evaluated in a Phase 1 clinical trial in China (NCT06443489), showing an overall response rate of ~73% among evaluable SCLC patients at therapeutic dose levels. Treatment-related adverse events (TRAEs) were predominantly Grade 1 or 2, and no dose-limiting toxicities were reported. SHR-4849 has demonstrated potential in preclinical studies and early clinical trials, including tumor regression and manageable safety. IDEAYA plans to file a US IND for SHR-4849 in H1 2025.

IDEAYA aims to explore SHR-4849 as a monotherapy in SCLC and NETs and in combination with IDE161, its PARG inhibitor, for enhanced efficacy. Hengrui Pharma will receive up to $1.045 billion in milestone payments, including a $75M upfront payment and royalties on net sales outside Greater China. IDEAYA’s cash runway is projected to last through 2028.

Hengrui Pharma is a global leader in innovative drug development with expertise in ADCs, PROTACs, bispecific antibodies, and AI molecular design. Its commitment to addressing unmet clinical needs aligns with IDEAYA’s precision medicine approach, which integrates molecular diagnostics and synthetic lethality to develop targeted cancer therapeutics.